PMID-37385279 — PIONEER PLUS: Oral Semaglutide 25/50 mg vs 14 mg in T2D (Phase 3b)

[DRAFT — authored 2026-04-19. Citation verified against PubMed/Lancet 2026-04-19.]

Citation

Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, Pedersen SD, Buse JB. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet. 2023;402(10403):693-704. doi: 10.1016/S0140-6736(23)01127-3. PMID: 37385279.

External URL: PubMed

Study Design

Design: Multicenter, randomized, double-blind, phase 3b trial
Setting: 177 sites in 14 countries
Population: Adults with T2D, HbA1c 8.0-10.5%, BMI ≥25 kg/m², receiving stable doses of 1-3 oral glucose-lowering drugs
Intervention: Oral semaglutide 14 mg, 25 mg, or 50 mg once daily × 68 weeks
Primary endpoint: Change in HbA1c from baseline to week 52
Secondary: Body weight change, HbA1c target attainment

Key Findings

HbA1c reductions (from mean baseline 9.0%)

Dose	HbA1c reduction at wk 52
Oral sem 14 mg	−1.5 percentage points
Oral sem 25 mg	−1.9 percentage points
Oral sem 50 mg	−2.2 percentage points

Body weight reductions (from mean baseline 96.4 kg)

Dose	Weight reduction at wk 52
Oral sem 14 mg	−4.5 kg
Oral sem 25 mg	−7.0 kg
Oral sem 50 mg	−9.2 kg

Statistical significance

Both 25 mg and 50 mg oral semaglutide were statistically superior to 14 mg for both HbA1c and weight reduction
No new safety concerns identified; GI events dose-dependent as expected

Clinical Relevance

PIONEER PLUS is the pivotal Phase 3b trial establishing that higher doses of oral semaglutide (25 mg and 50 mg) provide clinically meaningful additional HbA1c and weight benefits beyond the currently approved 14 mg dose. Core points:

Dose-response is real — both HbA1c and weight reduction increase dose-dependently from 14 mg to 50 mg
Regulatory pathway — results support FDA / EMA review of 25 mg and 50 mg oral sem labels for T2D
Companion to OASIS 4 (PMID: 40934115) — OASIS 4 studied 25 mg oral sem in obesity without T2D, demonstrating similar weight-loss magnitude (~13-16% at wk 64). Together PIONEER PLUS + OASIS 4 establish the oral Wegovy / higher-dose oral semaglutide story.
Novo Nordisk filing — regulatory approvals anticipated in 2023-2024 following these data; oral Wegovy (25 mg) submitted to FDA based on OASIS 4; oral semaglutide T2D 25/50 mg being considered per this data.

Linked Peptides

Semaglutide

Related Lessons

Lesson 5.2 — Semaglutide Deep Dive (oral formulation section)
Lesson 5.3 — Context for oral-vs-injectable decision framework

Related Studies

PMID-40934115 – OASIS 4 Wharton Oral Semaglutide 25mg Obesity — OASIS 4 companion in non-T2D obesity
PMID-37385278 – OASIS 1 Oral Semaglutide 50mg for Obesity — OASIS 1 50 mg oral for obesity
PMID-31185157 – PIONEER-6 Oral Semaglutide CV Outcomes — oral sem CV safety
PMID-40162642 – SOUL Oral Semaglutide CV Outcomes — oral sem CV benefit (14 mg)

PMID-37385279 – PIONEER PLUS Aroda Oral Semaglutide 25mg 50mg T2D